(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Tuesday.
AIM - WINNERS
Tavistock Investments, up 20% at 2.28 pence, 12-month range 1.00p-2.40p. The Bracknell-based fund manager says its financial performance during the pandemic has been "resilient", and it expects to report full-year earnings growth. Tavistock expects earnings before interest, tax, depreciation and amortisation for the financial year to March 31 to be "significantly ahead" of last year.
Pressure Technologies, up 14% at 100.02 pence, 12-month range 50.10p-147.00p. Its subsidiary Chesterfield Special Cylinders secures a contract with Haskel Hydrogen Group for the supply of high-pressure type-one steel vessels. The vessels will be used for hydrogen storage in three new hydrogen refuelling stations.
Joules Group, up 6.3% at 170.00 pence, 12-month range 32.80p-188.00p. The retailer buys Garden Trading Co for up to GBP12.5 million. The consideration will comprise an upfront payment of GBP9 million, of which GBP4.5 million will be paid in cash and the remainder in 2.8 million Joules shares. The deferred consideration is for up to GBP3.5 million, of which at least GBP3 million will be paid in cash and the rest either in cash or shares. Garden Trading is a home and garden products retailer.
Alba Mineral Resources, up 9.0% at 0.39 pence, 12-month range 0.040p-0.580p. Reports on testwork at its Amitsoq graphite asset in Greenland. Results confirm that graphite content at the project "is very high, amongst the highest found in flake graphite deposits globally".
AIM - LOSERS
Immupharma, down 14% at 10.15p, 12-month range 7.01p-21.39p. The London-based pharmaceutical development company says it has received feedback from the US health regulators regarding plans for a phase three trial of Lupus treatment Lupuzor. Immupharma noted a US Food & Drug Administration special protocol assessment will not be applicable and a conditional approval of Lupuzor, "has not been confirmed at this time". An FDA special protocol assessment refers to when a trial's clinical endpoints and design are approved. Immupharma adds it is on track to begin the phase 3 study in the second half of 2021.
By Eric Cunha; email@example.com
Copyright 2021 Alliance News Limited. All Rights Reserved.